Janus Henderson Group PLC Purchases 156,912 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Janus Henderson Group PLC boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 702,085 shares of the biopharmaceutical company's stock after buying an additional 156,912 shares during the quarter. Janus Henderson Group PLC owned approximately 0.55% of Halozyme Therapeutics worth $33,566,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Gotham Asset Management LLC boosted its stake in shares of Halozyme Therapeutics by 9.7% during the 4th quarter. Gotham Asset Management LLC now owns 47,440 shares of the biopharmaceutical company's stock worth $2,268,000 after acquiring an additional 4,178 shares during the period. Clark Capital Management Group Inc. lifted its holdings in Halozyme Therapeutics by 30.4% during the 4th quarter. Clark Capital Management Group Inc. now owns 178,827 shares of the biopharmaceutical company's stock valued at $8,550,000 after purchasing an additional 41,655 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its position in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after purchasing an additional 524,802 shares during the period. EP Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 8.5% in the fourth quarter. EP Wealth Advisors LLC now owns 6,769 shares of the biopharmaceutical company's stock valued at $324,000 after purchasing an additional 533 shares during the last quarter. Finally, CoreCap Advisors LLC raised its position in shares of Halozyme Therapeutics by 36.6% in the fourth quarter. CoreCap Advisors LLC now owns 15,831 shares of the biopharmaceutical company's stock valued at $757,000 after purchasing an additional 4,242 shares during the period. Institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $73.00 to $62.00 in a research report on Wednesday, May 14th. Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Finally, Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics has an average rating of "Hold" and a consensus target price of $61.90.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the sale, the senior vice president now directly owns 185,453 shares of the company's stock, valued at approximately $10,765,546.65. The trade was a 5.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. The trade was a 12.95% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,697 shares of company stock worth $1,276,552 over the last three months. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO traded down $0.11 during midday trading on Tuesday, hitting $53.19. The company had a trading volume of 355,771 shares, compared to its average volume of 1,601,714. The firm has a 50-day moving average price of $60.54 and a 200-day moving average price of $55.95. The company has a market capitalization of $6.55 billion, a PE ratio of 15.48, a P/E/G ratio of 0.42 and a beta of 1.26. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.98 by $0.13. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business's revenue for the quarter was up 35.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.79 EPS. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.